SGLT-2 inhibitors and high-dose acarbose as potential high-risk combinations for ketosis and ketoacidosis in Asian patients with T2DM: A case series.
SGLT-2 抑制劑與高劑量 acarbose 作為亞洲 T2DM 患者酮症和酮酸中毒的潛在高風險組合:案例系列。
Clin Case Rep 2024-09-13
A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care.
次級護理中使用鈉葡萄糖共同轉運蛋白-2抑製劑相關的一系列糖尿病酮酸中毒。
Diabetes Metab Syndr 2023-01-05
Severe euglycemic diabetic ketoacidosis secondary to sodium-glucose co-transporter 2 inhibitor: case report and literature review.
嚴重的正糖尿病酮酸中毒次級於鈉葡萄糖共同運輸蛋白2抑制劑:病例報告與文獻回顧。
Ann Med Surg (Lond) 2023-05-30
The risk factors of diabetic ketosis and diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors: a retrospective study.
接受 SGLT2 抑制劑治療的 2 型糖尿病患者發生糖尿病酮症和糖尿病酮酸中毒的風險因素:一項回顧性研究。
Expert Opin Drug Saf 2024-02-14
Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Associated Diabetic Ketoacidosis in Oncology Patients: A Case Series and Literature Review.
腫瘤患者中與鈉葡萄糖共轉運輔助蛋白2抑制劑(SGLT2i)相關的糖尿病酮酸中毒:病例系列及文獻回顧。
Cureus 2024-03-12
Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis.
平衡風險與益處:鈉葡萄糖共轉運輸蛋白2抑制劑與糖尿病酮酸中毒的風險。
Metabolites 2024-03-29
Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights.
SGLT2 抑制劑導致的糖尿病酮酸中毒:現實世界的洞察。
Diabetes Metab J 2024-06-10